Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men

Cited by (228)

Items 101–200 of 228

1. GLP−1 Promotes Cortical and Medullary Perfusion in the Human Kidney and Maintains Renal Oxygenation During NaCl Loading
   Haddock, Bryan, Kristensen, Kasper B., Tayyab, Mahvish, Larsson, Henrik B. W., Lindberg, Ulrich, Vestergaard, Mark, Francis, Susan, Jensen, Boye L., Andersen, Ulrik B., Asmar, Ali · 2023 · Journal of the American Heart Association
2. Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists
   Philippa Trevella, Elif Ilhan Ekinci, Richard J. MacIsaac · 2024 · Nephrology
3. Cardiorenal Protection in Diabetic Kidney Disease
   Jason F. Lee, Ecaterina Berzan, Vikas S. Sridhar, Ayodele Odutayo, David Z.I. Cherney · 2021 · Endocrinology and Metabolism
4. Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity
   Dilek Yazıcı, Hale Yapıcı Eser, Sinem Kucuksarac Kiyici, Seda Sancak, Havva Sezer, Melin Uygur, Volkan Yumuk · 2022 · Obesity Facts
5. New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review
   Jorge Jalil, Luigi Gabrielli, María Paz Ocaranza, Paul MacNab, Rodrigo Fernández, Bruno A. Grassi, Paulina Jofré, Hugo Verdejo, Mónica Acevedo B, Samuel Córdova A et al. · 2024 · International Journal of Molecular Sciences
6. Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators
   Ajay Chaudhuri, Husam Ghanim, Antoine Makdissi, Kelly Green, Sanaa Abuaysheh, Manav Batra, Nitesh D Kuhadiya, Paresh Dandona · 2016 · Diabetes Obesity and Metabolism
7. Inhibition of interleukin-6 on matrix protein production by glomerular mesangial cells and the pathway involved
   Sarika K. Chaudhari, Parisa Yazdizadeh Shotorbani, Yu Tao, Mark E. Davis, Robert T. Mallet, Rong Ma · 2020 · American Journal of Physiology-Renal Physiology
8. Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure
   Daniel F. Arruda-Junior, Flavia L. Martins, Rafael Dariolli, Leonardo Jensen, Ednei Luiz Antônio, Leonardo dos SANTOS, Paulo José Ferreira Tucci, Adriana C. C. Girardi · 2016 · Frontiers in Physiology
9. Effects of incretin-based therapies on renal function
   Vasilis Tsimihodimos, Moses Elisaf · 2017 · European Journal of Pharmacology
10. Physiology of the Incretin Hormones, GIP and GLP ‐1—Regulation of Release and Posttranslational Modifications
    Jens Juul Holst, Nicolai J Wewer Albrechtsen, METTE MARIE ROSENKILDE, Carolyn Fiona Deacon · 2019 · Comprehensive physiology
11. Renal Tubular Glucagon-Like Peptide-1 Receptor Expression Is Increased in Early Sepsis but Reduced in Chronic Kidney Disease and Sepsis-Induced Kidney Injury
    Jae Hyun Choi, Seung-Jung Kim, Soon Kil Kwon, Hye‐Young Kim, Hyun‐Jung Jeon · 2019 · International Journal of Molecular Sciences
12. Liraglutide Improves the Kidney Function in a Murine Model of Chronic Kidney Disease
    Maria Katarina Ougaard, Frederikke Emilie Sembach, Henrik Elvang Jensen, Charles Pyke, Lotte Bjerre Knudsen, Peter Helding Kvist · 2020 · The Nephron journals/Nephron journals
13. DPP4 Deficiency Preserved Cardiac Function in Abdominal Aortic Banding Rats
    Hui-Chun Ku, Ming‐Jai Su · 2014 · PLoS ONE
14. The GLP-1-mediated gut-kidney cross talk in humans: mechanistic insight
    Gitte R. Hinrichs, Peter Hambak Hovind, Ali Asmar · 2023 · American Journal of Physiology-Cell Physiology
15. Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin
    Scott Culver Thomson, Ali Kashkouli, Zhi Zhao Liu, Prabhleen Singh · 2017 · American Journal of Physiology-Renal Physiology
16. The Interplay Between Nonalcoholic Fatty Liver Disease and Kidney Disease
    Emily Truong, Mazen Noureddin · 2022 · Clinics in Liver Disease
17. Acute effects of glucagon-like peptide-1, GLP-19-36 amide, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers
    Lasse Bremholm, Ulrik Bjørn Andersen, Mads Hornum, Linda Hilsted, Simon Veedfald, Bolette Hartmann, Jens Juul Holst · 2017 · Physiological Reports
18. Activation of the renal GLP‐1R leads to expression of <i>Ren1</i> in the renal vascular tree
    Bjørnholm, Katrine Dahl, Ougaard, Maria Elm, Skovsted, Gry Freja, Knudsen, Lotte Bjerre, Pyke, Charles · 2021 · Endocrinology, Diabetes &amp; Metabolism
19. Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP‐1 but not GIP, CCK, and gastrin in plasma
    Ali Asmar, Per Karkov Cramon, Meena Asmar, Lene Simonsen, Charlotte Mehlin Sørensen, Sten Madsbad, Cédric Moro, Bolette Hartmann, Jens Frederik Rehfeld, Jens Juul Holst et al. · 2020 · Physiological Reports
20. Anti-atherosclerotic effect of incretin receptor agonists
    Xin Wang, Xin Yang, Xiaoyan Qi, Gang Fan, Lingzhi Zhou, Zhengliang Peng, Jing Yang · 2024 · Frontiers in Endocrinology
21. Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease
    Kim Alexander Connelly, Bridgit B. Bowskill, Suzanne L. Advani, Kerri Thai, Li-Hao Chen, M. Golam Kabir, Richard E. Gilbert, Andrew Advani · 2014 · Clinical and investigative medicine
22. Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?
    Yoshio Sumida, Masashi Yoneda, Hidenori Toyoda, Satoshi Yasuda, Toshifumi Tada, Hideki Hayashi, Yoichi Nishigaki, Yusuke Suzuki, Takafumi Naiki, Asahiro Morishita et al. · 2020 · International Journal of Molecular Sciences
23. Dipeptidyl peptidase-4 inhibitors in progressive kidney disease
    Yuichi Makino, Yukihiro Fujita, Masakazu Haneda · 2014 · Current Opinion in Nephrology & Hypertension
24. Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?
    Milton Packer · 2025 · European Heart Journal
25. Incretin and glucagon receptor polypharmacology in chronic kidney disease
    Brandon E. McFarlin, Kevin L. Duffin, Anish A. Konkar · 2024 · American Journal of Physiology-Endocrinology and Metabolism
26. Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist
    Courtney J. Riedinger, Julia C. Sakach, Jill M. Maples, Jessica Fulton, Jessica Chippior, Benjamin OʼDonnell, David M. O’Malley, Laura Chambers · 2024 · Gynecologic Oncology
27. Incretin-based therapies and renin-angiotensin system: Looking for new therapeutic potentials in the diabetic milieu
    Habib Yaribeygi, Mina Maleki, Thozhukat Sathyapalan, Tannaz Jamialahmadi, Amirhossein Sahebkar · 2020 · Life Sciences
28. Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial
    Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, Mark H.H. Kramer, D. Margriet Ouwens, Bolette Hartmann, Jens Juul Holst, Daan Johannes Touw, A.H. Jan Danser, Jaap A. Joles et al. · 2020 · Diabetes Care
29. GLP-1 Receptor Agonists in Heart Failure
    Ali Reza Rahmani, Simrat Dhaliwal, Paola Pastena, Eliot Kazakov, Keerthana Jayaseelan, Andreas P. Kalogeropoulos · 2025 · Biomolecules
30. GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
    Radica Z. Alicic, Joshua J. Neumiller, Katherine R. Tuttle · 2026 · Nature Reviews Nephrology
31. Glucagon-like peptide-1 receptor agonism and end-organ protection
    Samuel Joseph Daniels, Cecilia Karlsson, Patrick Schrauwen, Victoria Parker · 2025 · Trends in Endocrinology and Metabolism
32. Combining incretin-based drugs and RAAS inhibitors: more cons than pros?
    Lennart Tonneijck, Marcel H.A. Muskiet, Mark M. Smits, Daniël H. van Raalte, Michaëla Diamant · 2014 · The Lancet Diabetes & Endocrinology
33. Glucagon-like peptide-1 inhibits the receptor for advanced glycation endproducts to prevent podocyte apoptosis induced by advanced oxidative protein products
    Shuang‐Shuang Zhang, Zhou Wu, Zhen Zhang, Zhou-Yi Xiong, Hong Chen, Qiaobing Huang · 2016 · Biochemical and Biophysical Research Communications
34. Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies
    Wenwen Zheng, Qianxian Qi, Jie Li, Chao‐Jie He, Hongyan Fan · 2025 · Diabetology & Metabolic Syndrome
35. The dual impact of GLP-1 receptor agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials
    Bassel H. Hoteit, Jana Kotaich, Hadi Ftouni, Fatima Hazime, Abdallah Safawi, Rim Masri, Mia Marwani · 2025 · Therapeutic Advances in Endocrinology and Metabolism
36. Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes
    HARPREET SINGH BAJAJ, Badr A. Aljabri, Subodh Verma · 2018 · Current Opinion in Cardiology
37. Glucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
    Domenico Tricò, Anna Solini · 2021 · Advances in Chronic Kidney Disease
38. GLP-1 and the renin–angiotensin–aldosterone system
    David León Jiménez, Miguel Camafort, José Pablo Miramontes‐González · 2019 · The Lancet Diabetes & Endocrinology
39. Effect of Salt Intake on Serum Glucagon-Like Peptide-1 Levels in Normotensive Salt-Sensitive Subjects
    Wenling Zheng, Chao Chu, Yong-Bo Lv, Yang Wang, Jiawen Hu, Qiong Ma, Yu Yan, Yu-Meng Cao, Xi-Long Dang, Keke Wang et al. · 2017 · Kidney & Blood Pressure Research
40. Effects of exendin-4 on the intrarenal renin-angiotensin system and interstitial fibrosis in unilateral ureteral obstruction mice: Exendin-4 and unilateral ureteral obstruction
    Ying Le, Zongji Zheng, Junyu Xue, Mengling Cheng, Meiping Guan, Yaoming Xue · 2016 · Journal of the Renin-Angiotensin-Aldosterone System
41. Glucagon-Like Peptide-1 Infusion Suppresses Aldosterone Levels in Healthy Normal-Weight Individuals: Double-Blind, Placebo-Controlled Crossover Study
    Maja Baretić, Vesna Kuŝec, Ivana Pavlić-Renar · 2018 · Diabetes Therapy
42. Incretin-based drugs and renoprotection—is hyperfiltration key?
    Lennart Tonneijck, Mark M. Smits, Daniël H. van Raalte, Marcel H.A. Muskiet · 2015 · Kidney International
43. Incretin-based therapy: a new horizon in diabetes management
    Malek Zarei, Navideh Sahebi Vaighan, Mohammad Hadi Farjoo, Soosan Talebi, Mohammad Zarei · 2024 · Journal of Diabetes & Metabolic Disorders
44. Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction
    Tianyu Wang, Qiang Yang, Xin-Yi Cheng, Jun-Can Ding, Peng-Fei Hu · 2024 · Heart Failure Reviews
45. Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
    Jean‐Philippe Krieger, Derek Daniels, Shin Jae Lee, Svetlana Mastitskaya, Wolfgang Langhans · 2024 · Comprehensive physiology
46. Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats
    Rubén Rodríguez, Meagan Moreno, Andrew Y. Lee, José A. Godoy-Lugo, Daisuke Nakano, Akira Nishiyama, David G. Parkes, Mouhamed S. Awayda, Rudy Martin Ortiz · 2018 · Hypertension Research
47. Decreased expression of the GLP-1 receptor after segmental artery injury in mice
    Bjørnholm, Katrine Dahl, Povlsen, Gro Klitgaard, Ougaard, Maria Elm, Pyke, Charles, Rakipovski, Günaj, Tveden-Nyborg, Pernille, Lykkesfeldt, Jens, Skovsted, Gry Freja · 2021 · Journal of Endocrinology
48. Glucagon-like peptide-1 receptor agonists in neoplastic diseases
    Lisan Ji, Xianzhen He, Xinwen Min, Handong Yang, Wenwen Wu, Hao Xu, Jun Chen, Aihua Mei · 2024 · Frontiers in Endocrinology
49. Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action
    Bykova Aa, Maria Serova, M. I. Chashkina, Raisa S. Kosharnaia, Z. K. Salpagarova, Denis A. Andreev, Ilya Giverts · 2024 · Cardiac failure review
50. Associations between changes in glucagon‐like peptide‐1 and bodyweight reduction in patients receiving acarbose or metformin treatment
    Na Wang, Jinping Zhang, Xiaoyan Xing, Zhaojun Yang, Bo Zhang, Xin Wang, Wen‐Ying Yang · 2016 · Journal of Diabetes
51. The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes
    Zengguang Kuang, Ningning Hou, Chengxia Kan, Fang Han, Hongyan Qiu, Xiaodong Sun · 2022 · International Urology and Nephrology
52. GLP-1 infusion reduces IGFBP-1 serum level in humans
    Jeppe Skov, Jan Frystyk, Jens Sandahl Christiansen · 2014 · Growth Hormone & IGF Research
53. Hypertension and Diabetic Nephropathy
    Jeppe Skov, Jens Sandahl Christiansen, Per Løgstrup Poulsen · 2016 · Endocrine development
54. Higher Screening Aldosterone to Renin Ratio in Primary Aldosteronism Patients with Diabetes Mellitus
    Chia‐Hui Chang, Ya‐Hui Hu, Kuo‐How Huang, Yen‐Hung Lin, Yao‐Chou Tsai, Che‐Hsiung Wu, Shao‐Yu Yang, Chin‐Chen Chang, Ching‐Chu Lu, Kwan‐Dun Wu et al. · 2018 · Journal of Clinical Medicine
55. Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients
    Sten Madsbad · 2019 · Expert Review of Cardiovascular Therapy
56. Stroke in the Patient With Type 2 Diabetes
    Terri W. Jerkins, David S.H. Bell · 2025 · Endocrine Practice
57. Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease
    Sung‐Min Kim, Jung Nam An, Young Rim Song, Sung Gyun Kim, Hyung‐Seok Lee, Ajin Cho, Jwa-Kyung Kim · 2022 · PLoS ONE
58. Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes ( RENALIS ): A predefined substudy of a randomized, double‐blind trial
    Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, Mark H.H. Kramer, D. Margriet Ouwens, Bolette Hartmann, Jens Juul Holst, A.H. Jan Danser, Jaap A. Joles, Daniël H. van Raalte · 2021 · Diabetes Obesity and Metabolism
59. Effect of glucagon‐like peptide‐1 receptor agonists on renal function: A meta‐analysis of randomized controlled trials
    Mario Alberto Simental-Mendía, Enrique Linden‐Torres, Adriana Sánchez‐García, Amirhossein Sahebkar, Luis E. Simental‐Mendía · 2022 · British Journal of Clinical Pharmacology
60. Inhibition of notch signalling and mesangial expansion by combined glucagon like peptide-1 agonist and crocin therapy in animal model of diabetic nephropathy
    Shaimaa Nasr Amin, Eman Mumtaz El-Gamal, Laila Ahmed Rashed, Samaa Samir Kamar, Maged Ahmed Haroun · 2020 · Archives of Physiology and Biochemistry
61. Obesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists
    Tirandi, Amedeo, Montecucco, Fabrizio, Carbone, Federico, Liberale, Luca · 2024 · Polish Archives of Internal Medicine
62. Renal disease in patients with type 2 diabetes: Magnitude of the problem, risk factors and preventive strategies
    Luigi Gnudi · 2022 · La Presse Médicale
63. Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials
    Jingyi Guo, Maoying Wei, Wen‐Hua Zhang, Yijia Jiang, Aijing Li, Churan Wang, Dan Yin, Anning Sun, Yanbing Gong · 2025 · Frontiers in Pharmacology
64. Does growth differentiation factor 11 protect against myocardial ischaemia/reperfusion injury? A hypothesis
    Yongjian Yang, Yi Yang, Xiong Wang, Jin Du, Juanni Hou, Juan Feng, Yue Tian, Lei He, Xiuchuan Li, Haifeng Pei · 2016 · Journal of International Medical Research
65. Natriuretic peptide system in hypertension: Current understandings of its regulation, targeted therapies and future challenges
    Vishwadeep Shelke, Neha Dagar, Bhupendra Puri, Anil Bhanudas Gaikwad · 2024 · European Journal of Pharmacology
66. Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers
    Sok Cin Tye, Sieta T. de Vries, Johannes F.E. Mann, Meir Schechter, Ofri Mosenzon, Petra Denig, Hiddo J.L. Heerspink · 2022 · Frontiers in Pharmacology
67. Diabetic Kidney Disease: From Pathophysiology to Regression of Albuminuria and Kidney Damage: Is It Possible?
    Georgia Doumani, Panagiotis Theofilis, Aikaterini Vordoni, Vasileios Thymis, George Liapis, Despina Smirloglou, Rigas Kalaitzidis · 2025 · International Journal of Molecular Sciences
68. The influence of insulin and incretin-based therapies on renal tubular transport
    Erica Rosati, Gianfranco Di Giuseppe, Teresa Mezza, Pietro Manuel Ferraro · 2024 · Journal of Nephrology
69. Addressing Renal Sodium Avidity in Chronic Heart Failure: There Is Always More than One Way to Skin a Cat
    Marco Montomoli, Miguel González, José Luis Górriz, María Jesús Puchades Montesa, Gonzalo Nuñez Marín, Ma Soledad Lecueder · 2025 · Cardiorenal Medicine
70. Extrahepatic manifestation of metabolic dysfunction-associated steatotic liver disease
    Anoushka Shenoy, Aijaz Ahmed, Donghee Kim · 2025 · Metabolism and Target Organ Damage
71. Effects of GLP-1 receptor agonists on copeptin in euvolemic participants
    Svenja Leibnitz, Bettina Felicitas Winzeler, Julie Celine Refardt, D. Vogt, Clara Odilia Sailer, Mirjam Christ‐Crain · 2026 · European Journal of Endocrinology
72. Early treatment with GLP-1 after severe trauma preserves renal function in obese Zucker rats
    Lusha Xiang, Michael S. Thompson, John S. Clemmer, Peter N. Mittwede, T. M. Khan, Robert L. Hester · 2019 · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
73. Possible mechanisms of action of glucagon-like peptide-1 receptor agonists on blood pressure beyond body weight
    Masami Tanaka, Hiroshi Itoh · 2025 · Hypertension Research
74. Current and Emerging Roles of GLP1 Receptor Agonists Across the Spectrum of Left Ventricular Ejection Fraction in Heart Failure
    Simone Pasquale Crispino, Annunziata Nusca, Aurora Ferro, Riccardo Cricco, Martina Ciancio, Andrea Segreti, Ilaria Cavallari, Mario Sabatino, Luciano Potena, Gian Paolo Ussia et al. · 2025 · Biomolecules
75. Association of GLP-1 receptor agonists versus bariatric surgery with outcomes in obese patients with hypertrophic cardiomyopathy: a multicenter propensity-matched analysis
    Ahmed Mahmoud, Kamal Awad, Hesham Sheashaa, Omneya Kandil, Juan Farina, Ramzi Ibrahim, Mahmoud Abdelnabi, Mohamed Allam, Rohit Mital, Justin N. Shipman et al. · 2026 · European Heart Journal - Quality of Care and Clinical Outcomes
76. Lithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations
    Ervin Michelstaedter Cotrik, Antônio Geraldo da Silva, Jair C. Soares · 2026 · International Clinical Psychopharmacology
77. Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants
    Tanja Vukajlovic, Clara Odilia Sailer, Ali Asmar, Boye Lagerbon Jensen, D. Vogt, Mirjam Christ‐Crain, Bettina Felicitas Winzeler · 2022 · The Journal of Clinical Endocrinology & Metabolism
78. Fasting GLP-1 Levels and Albuminuria Are Negatively Associated in Patients with Type 2 Diabetes Mellitus
    Cheol-Won Jang, Tae Yang Yu, Jin Woo Jeong, Se Eun Ha, Rajan Singh, Moon Young Lee, Seungil Ro · 2024 · Journal of Personalized Medicine
79. GLP-1 receptor agonists—another promising therapy for Alport syndrome?
    Jan Boeckhaus, Holly R. Mabillard, John Andrew Sayer · 2025 · Journal of Rare Diseases
80. New and developing pharmacotherapies for hypertension
    Christián Höcht, Miguel Ángel Allo, Ariel Héctor Polizio, Marcela Analia Moretton, Andrea Carranza, Diego A. Chiappetta, Marcelo R. Choi · 2022 · Expert Review of Cardiovascular Therapy
81. NFAT5 Is Involved in GRP-Enhanced Secretion of GLP-1 by Sodium
    Caini Fan, Laureano D. Asico, Van Anthony M. Villar, Jessica Hunt, Santiago Cuevas, Inés Armando, Pedro A. José, Prasad R. Konkalmatt · 2021 · International Journal of Molecular Sciences
82. Glucagon-like peptide-1 agonists alleviate adenine-induced nephrotoxicity in rats: interaction with the renin-angiotensin system and role of NLRP-3 inflammasome, nephrin and KIM-1
    Hisham A. Nematalla, Mona Elharoun, Eman Sheta, Samar R. Saleh, Marianne Basta, Ali Hussein Eid, Ahmed Fawzy EL‐Yazbi · 2025 · Biochemical Pharmacology
83. The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review
    Dhir Gala, Fady Botros, Amgad N. Makaryus · 2025 · Reviews in Cardiovascular Medicine
84. The effects of glucagon-like peptide-1 receptor agonists on sympathetic neuron activity
    Yui Koyanagi, Kamon Iigaya, Keiko Ikeda, Hiroshi Onimaru, Masahiko Izumizaki · 2026 · Hypertension Research
85. GLP-1 receptor agonist-induced transient retinal perfusion delay and its potential mediation by intracranial pressure
    Yun Kyung Lee, Yuan Yi Chang, Han Na Jang, Dae Joong Ma, Hyun Beom Song · 2026 · Biomedicine & Pharmacotherapy
86. Question
    Jonathan G. Leung · 2026 · Journal of Clinical Psychopharmacology
87. Could Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Play a Role in Gout Treatment?
    Dan Kaufmann, Naomi Schlesinger · 2025 · Pharmaceutics
88. Clinical factors influencing the systolic blood pressure benefits of once-weekly semaglutide in patients with type 2 diabetes
    Jorge Gabriel Ruiz-Sánchez, Roberto Sierra-Poyatos, Bogdana Luiza Luca, Begoña Sánchez-Lechuga, Naiara Modroño Móstoles, Teresa Montoya Álvarez, Diego Meneses, Raquel Sánchez-Lopez, Carlos Casado Cases, Víctor Pérez de Arenaza Pozo et al. · 2025 · Medicina Clínica
89. An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon‐like peptide‐1 and glucagon receptor in healthy subjects
    James A Goodman, Victoria Parker, Carmel M. McEniery, Giovanni Di Stefano, Annette Hubsch, Evangelia Vamvaka, Jo Helmy, Fotini Kaloyirou, Navazh Jalaludeen, Peter Barker et al. · 2025 · British Journal of Clinical Pharmacology
90. Link of Obesity With Primary Aldosteronism: Causal or Not?
    John M. Flack, Michael Buhnerkempe, Angel Lopez, James Brian Byrd · 2026 · Hypertension
91. The role of gut microbiome disruption in the development of metabolic dysfunction-associated kidney disease
    Michał Witkowski, Jarosław Przybyciński, Bartosz Wojciuk, Wiktor Czaja, Natalia Gołembiewska, Edyta Gołembiewska · 2026 · Acta Biochimica Polonica
92. KDOQI Commentary on the 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
    Tara I. Chang, Jennifer Cluett, Debbie L. Cohen, Paul E. Drawz, Joanna Q. Hudson, Holly Kramer, Mahboob Rahman, Linda Awdishu · 2026 · American Journal of Kidney Diseases
93. Extrapancreatic Effect of Glucagon like Peptide-1
    In‐Kyung Jeong · 2015 · Korean Journal of Medicine
94. Nonglycemic effects of incretins in patients with long-term type 1 diabetes mellitus and chronic kidney disease
    Margarita Arutyunova, Alexandra Michailovna Glazunova, Olga Mikhaleva, Z. T. Zuraeva, Sergey Andreevich Martynov, Inna Igorevna Klefortova, O.V. Manchenko, Irina Nikolaevna Ul'yanova, А V Ilyin, Минара Шамхаловна Шамхалова et al. · 2015 · Terapevticheskii arkhiv
95. Renoprotection in diabetic kidney disease
    Michaël J.B. van Baar, Daniël H. van Raalte · 2019 · Current Opinion in Nephrology & Hypertension
96. Histomorphologie und Pathogenese der diabetischen Nephropathie
    Kerstin Amann, Christoph Daniel · 2020 · Der Nephrologe
97. Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications
    Anniek Frederike Lubberding, Jens Juul Holst, Sten Madsbad · 2023 · Elsevier eBooks
98. High Dose of Liraglutide Impairs Renal Function in Female Hypertensive Rats
    Felipe Tonon Firmino, Pollyana Peixoto, Thatiany Jardim Batista, Leonardo da Silva Escouto, Girlândia Alexandre Brasil, Mariana dos Reis Couto, Antônio Ferreira de Melo, Nazaré Souza Bissoli · 2024 · Journal of Cardiovascular Pharmacology
99. Inflammatory Mechanisms in Diabetic Kidney Disease
    Radica Z. Alicic, Emily J. Cox, Joshua J. Neumiller, Katherine R. Tuttle · 2020 · Springer eBooks
100. Combining incretin-based drugs and RAAS inhibitors: more cons than pros?
     Lina Zgaga · 2014